03:57 AM EST, 03/06/2025 (MT Newswires) -- Aquestive Therapeutics ( AQST ) reported Q4 net loss Wednesday of $0.19 per share, widening from a loss of $0.12 a year earlier.

Two analysts polled by FactSet expected a loss of $0.14.

Revenue for the quarter ended Dec. 31 was $11.9 million, down from $13.2 million a year earlier.

Analysts surveyed by FactSet expected $13.1 million.

For the full-year 2025, the company said it expects total revenue in the range of $47 million to $56 million. Analysts polled by FactSet expect $53 million.

Aquestive's stock was down 4.3% in after-hours activity Wednesday.

Price: 2.67, Change: -0.12, Percent Change: -4.30